150
Participants
Start Date
August 19, 2025
Primary Completion Date
October 31, 2030
Study Completion Date
October 31, 2030
DZD8586+R-CHOP
DZD8586 at the protocol defined dose level (50 mg or 75 mg, po, qd) with R-CHOP (Rituximab: 375 mg/m2, IV, d1; Cyclophosphamide: 750 mg/m2, IV, d1; Doxorubicin: 50 mg/m2, IV, d1; Vincristine: 1.4 mg/m2, IV, d1; Prednisone: 100 mg, po, d1-5) in a 21-day cycle for 6 cycles. DZD8586 (pre-defined dose level, po, qd) as maintenance therapy for CR/PR patients.
DZD8586+R-GemOx
DZD8586 at the protocol defined dose level (50 mg or 75 mg, po, qd) with R-GemOx (Rituximab: 375 mg/m2, IV, d1; Gemcitabine: 1000 mg/m2, IV, d1; Oxaliplatin: 100 mg/m2, IV, d1) in a 21-day cycle for 8 cycles. DZD8586 (pre-defined dose level, po, qd) as maintenance therapy for CR/PR patients.
DZD8586+BR
DZD8586 at the protocol defined dose level (50 mg or 75 mg, po, qd) with BR (Bendamustine: 90 mg/m2, IV, d1-d2; Rituximab: 375 mg/m2, IV, d1) in a 21-day cycle for 6 cycles. DZD8586 (pre-defined dose level, po, qd) as maintenance therapy for CR/PR patients.
NOT_YET_RECRUITING
Peking University Third Hospital, Beijing
NOT_YET_RECRUITING
Hunan Cancer Hospital, Changsha
NOT_YET_RECRUITING
West China Hospital of Sichuan University, Chengdu
NOT_YET_RECRUITING
Chongqing Cancer Hospital, Chongqing
RECRUITING
Guangdong Provincial People's Hospital, Guangzhou
RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
RECRUITING
Zhujiang Hospital of Southern Medical University, Guangzhou
RECRUITING
The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou
RECRUITING
Anhui Provincial Cancer Hospital, Hefei
NOT_YET_RECRUITING
Shandong Cancer Hospital & Institute, Jinan
RECRUITING
Linyi Cancer Hospital, Linyi
NOT_YET_RECRUITING
Shengjing Hospital of China Medical University, Shenyang
NOT_YET_RECRUITING
Shanxi Cancer Hospital, Taiyuan
RECRUITING
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
NOT_YET_RECRUITING
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an
NOT_YET_RECRUITING
Henan Cancer Hospital, Zhengzhou
Lead Sponsor
Dizal Pharmaceuticals
INDUSTRY